Skip to main content
SpringerLink
Log in

Epigenetics and Ovarian Cancer

  • Chapter
  • First Online:
Ovarian Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 149))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–945.

    Google Scholar 

  2. Garber K. Momentum building for human epigenome project. J Natl Cancer Inst. 2006;98:84–86.

    Article  PubMed  Google Scholar 

  3. Jones P. A. DNA methylation and cancer. Oncogene. 2002;21:5358–5360.

    Article  CAS  PubMed  Google Scholar 

  4. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–196.

    Article  CAS  PubMed  Google Scholar 

  5. Bestor TH. The host defence function of genomic methylation patterns. Novartis Found Symp. 1998;214:187–195; discussion 195–189, 228–132.

    CAS  PubMed  Google Scholar 

  6. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–1159.

    Article  CAS  PubMed  Google Scholar 

  7. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002;62:7213–7218.

    CAS  PubMed  Google Scholar 

  8. Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 2004;191:1552–1572.

    Article  CAS  PubMed  Google Scholar 

  9. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007;128:669–681.

    Article  CAS  PubMed  Google Scholar 

  10. Turner BM. Cellular memory and the histone code. Cell. 2002;111:285–291.

    Article  CAS  PubMed  Google Scholar 

  11. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8:286–298.

    Article  CAS  PubMed  Google Scholar 

  12. Luscher-Firzlaff J, Gawlista I, Vervoorts J, et al. The human trithorax protein hASH2 functions as an oncoprotein. Cancer Res. 2008;68:749–758.

    Article  PubMed  CAS  Google Scholar 

  13. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846–856.

    Article  CAS  PubMed  Google Scholar 

  14. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006;125:315–326.

    Article  CAS  PubMed  Google Scholar 

  15. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet. 2007;39:237–242.

    Article  CAS  PubMed  Google Scholar 

  16. Ohm JE, Baylin SB. Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle. 2007;6:1040–1043.

    CAS  PubMed  Google Scholar 

  17. Balch C, Nephew KP, Huang TH, Bapat SA. Epigenetic “bivalently marked” process of cancer stem cell-driven tumorigenesis. Bioessays. 2007;29:842–845.

    Article  PubMed  Google Scholar 

  18. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7:21–33.

    Article  CAS  PubMed  Google Scholar 

  19. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261.

    Article  CAS  PubMed  Google Scholar 

  20. Vignali M, Hassan AH, Neely KE, Workman JL. ATP-dependent chromatin-remodeling complexes. Mol Cell Biol. 2000;20:1899–1910.

    Article  CAS  PubMed  Google Scholar 

  21. Roberts CW, Orkin SH. The SWI/SNF complex – chromatin and cancer. Nat Rev Cancer. 2004;4:133–142.

    CAS  PubMed  Google Scholar 

  22. Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J. NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem. 2006;281:15129–15137.

    Article  CAS  PubMed  Google Scholar 

  23. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell. 2004;16:861–865.

    Article  CAS  PubMed  Google Scholar 

  24. Murphy D, Dancis B, Brown JR. The evolution of core proteins involved in microRNA biogenesis. BMC Evol Biol. 2008;8:92.

    Article  PubMed  CAS  Google Scholar 

  25. Aravin AA, Hannon GJ, Brennecke J. The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science. 2007;318:761–764.

    Article  CAS  PubMed  Google Scholar 

  26. Seto AG, Kingston RE, Lau NC. The coming of age for Piwi proteins. Mol Cell. 2007;26:603–609.

    Article  CAS  PubMed  Google Scholar 

  27. Stadler BM, Ruohola-Baker H. Small RNAs: keeping stem cells in line. Cell. 2008;132:563–566.

    Article  CAS  PubMed  Google Scholar 

  28. Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9:219–230.

    Article  CAS  PubMed  Google Scholar 

  29. Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–269.

    Article  CAS  PubMed  Google Scholar 

  30. American Cancer Society, Key Statistics About Ovarian Cancer. American Cancer Society Center, 250 Williams Street, Atlanta, GA, 2006.

    Google Scholar 

  31. Bast RC, Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003;21:200–205.

    Article  Google Scholar 

  32. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3–11.

    Article  CAS  PubMed  Google Scholar 

  33. Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004;64:4472–4480.

    Article  CAS  PubMed  Google Scholar 

  34. Pattamadilok J, Huapai N, Rattanatanyong P, et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int J Gynecol Cancer. 2007;18:711–7.

    Google Scholar 

  35. Leu YW, Rahmatpanah F, Shi H, et al. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 2003;63:6110–6115.

    CAS  PubMed  Google Scholar 

  36. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol. 2008;109:129–139.

    Article  CAS  PubMed  Google Scholar 

  37. Feng W, Marquez RT, Lu Z, et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008;112:1489–1502.

    Article  CAS  PubMed  Google Scholar 

  38. Terasawa K, Sagae S, Toyota M, et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res. 2004;10:2000–2006.

    Article  CAS  PubMed  Google Scholar 

  39. Arnold JM, Cummings M, Purdie D, Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer. 2001;85:1351–1358.

    Article  CAS  PubMed  Google Scholar 

  40. Sellar GC, Watt KP, Rabiasz GJ, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet. 2003;34:337–343.

    Article  CAS  PubMed  Google Scholar 

  41. Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis. 2006;23:65–74.

    Article  PubMed  CAS  Google Scholar 

  42. Rong R, Jin W, Zhang J, Sheikh MS, Huang Y. Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene. 2004;23:8216–8230.

    Article  CAS  PubMed  Google Scholar 

  43. Backen AC, Cole CL, Lau SC, et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer. 2007;96:1544–1548.

    Article  CAS  PubMed  Google Scholar 

  44. Staub J, Chien J, Pan Y, et al. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene. 2007;26:4969–4978.

    Article  CAS  PubMed  Google Scholar 

  45. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol. 2001;158:2097–2106.

    CAS  PubMed  Google Scholar 

  46. Akahira J, Sugihashi Y, Suzuki T, et al. Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res. 2004;10:2687–2693.

    Article  CAS  PubMed  Google Scholar 

  47. Hatle KM, Neveu W, Dienz O, et al. Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression. Mol Cell Biol. 2007;27:2952–2966.

    Article  CAS  PubMed  Google Scholar 

  48. Shridhar V, Bible KC, Staub J, et al. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001;61:4258–4265.

    CAS  PubMed  Google Scholar 

  49. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 2003;63:664–673.

    CAS  PubMed  Google Scholar 

  50. Litkouhi B, Kwong J, Lo CM, et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia. 2007;9:304–314.

    Article  CAS  PubMed  Google Scholar 

  51. Rose SL, Fitzgerald MP, White NO, et al. Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol . 2006;102:319–324.

    Article  CAS  PubMed  Google Scholar 

  52. Yao X, Hu JF, Li T, et al. Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet. 2004;151:1–13.

    Article  CAS  PubMed  Google Scholar 

  53. LaVoie HA. Epigenetic control of ovarian function: the emerging role of histone modifications. Mol Cell Endocrinol. 2005;243:12–18.

    Article  CAS  PubMed  Google Scholar 

  54. Ozdag H, Teschendorff AE, Ahmed AA, et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics. 2006;7:90.

    Article  PubMed  CAS  Google Scholar 

  55. Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene. 2006;25:5446–5461.

    Article  CAS  PubMed  Google Scholar 

  56. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther. 2002;1:1181–1190.

    CAS  PubMed  Google Scholar 

  57. Abbosh PH, Montgomery JS, Starkey JA, et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 2006;66:5582–5591.

    Article  CAS  PubMed  Google Scholar 

  58. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008;47:701–6.

    Google Scholar 

  59. Shih Ie M, Sheu JJ, Santillan A, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA. 2005;102:14004–14009.

    Article  PubMed  CAS  Google Scholar 

  60. Davidson B, Trope CG, Wang TL, Shih Ie M. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 2006;103:814–819.

    Article  CAS  PubMed  Google Scholar 

  61. Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K, Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis. 2003;20:19–24.

    Article  CAS  PubMed  Google Scholar 

  62. Nawa A, Nishimori K, Lin P, et al. Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides. J Cell Biochem. 2000;79:202–212.

    Article  CAS  PubMed  Google Scholar 

  63. Bochar DA, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell. 2000;102:257–265.

    Article  CAS  PubMed  Google Scholar 

  64. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene. 2007;26:7058–7066.

    Article  CAS  PubMed  Google Scholar 

  65. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–8707.

    Article  CAS  PubMed  Google Scholar 

  66. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–433.

    Article  CAS  PubMed  Google Scholar 

  67. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 2008;105:7004–7009.

    Article  CAS  PubMed  Google Scholar 

  68. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res. 2006;12:2788–2794.

    Article  CAS  PubMed  Google Scholar 

  69. Muller HM, Millinger S, Fiegl H, et al. Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem. 2004;50:2171–2173.

    Article  PubMed  CAS  Google Scholar 

  70. Chan MW, Wei SH, Wen P, et al. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res. 2005;11:7376–7383.

    Article  CAS  PubMed  Google Scholar 

  71. Teodoridis JM, Hall J, Marsh S, et al. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005;65:8961–8967.

    Article  CAS  PubMed  Google Scholar 

  72. Makarla PB, Saboorian MH, Ashfaq R, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res. 2005;11:5365–5369.

    Article  CAS  PubMed  Google Scholar 

  73. Okochi-Takada E, Nakazawa K, Wakabayashi M, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer. 2006;119:1338–1344.

    Article  CAS  PubMed  Google Scholar 

  74. Fiegl H, Windbichler G, Mueller-Holzner E, et al. HOXA11 DNA methylation-A novel prognostic biomarker in ovarian cancer. Int J Cancer. 2008;123:729–9.

    Google Scholar 

  75. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10:4420–4426.

    Article  CAS  PubMed  Google Scholar 

  76. Ibanez de Caceres I, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64:6476–6481.

    Article  PubMed  Google Scholar 

  77. Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst. 2005;97:315–319.

    Article  CAS  PubMed  Google Scholar 

  78. Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol . 2006;49:433–447.

    Article  PubMed  Google Scholar 

  79. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001;134:573–586.

    CAS  PubMed  Google Scholar 

  80. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol. 2002;13:1699–1716.

    Article  CAS  PubMed  Google Scholar 

  81. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 2005;11:3604–3608.

    Article  CAS  PubMed  Google Scholar 

  82. Issa JP. Decitabine. Curr Opin Oncol. 2003;15:446–451.

    Article  CAS  PubMed  Google Scholar 

  83. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y, Dahiya R. Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol. 2003;202:201–207.

    CAS  PubMed  Google Scholar 

  84. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 2002;62:6456–6461.

    CAS  PubMed  Google Scholar 

  85. Balch C, Yan P, Craft T, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther. 2005;4:1505–1514.

    Article  CAS  PubMed  Google Scholar 

  86. Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007;67:6400–6408.

    Article  CAS  PubMed  Google Scholar 

  87. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol. 2005;68:1018–1030.

    Article  CAS  PubMed  Google Scholar 

  88. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res. 2003;9:1596–1603.

    CAS  PubMed  Google Scholar 

  89. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003;63:4984–4989.

    CAS  PubMed  Google Scholar 

  90. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202.

    Article  CAS  PubMed  Google Scholar 

  91. Zeng L, Zhang Y, Chien S, Liu X, Shyy JY. The role of p53 deacetylation in p21Waf1 regulation by laminar flow. J Biol Chem. 2003;278:24594–24599.

    Article  CAS  PubMed  Google Scholar 

  92. Blagosklonny MV, Robey R, Sackett DL, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther. 2002;1:937–941.

    CAS  PubMed  Google Scholar 

  93. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer. 2004;101:2760–2770.

    Article  CAS  PubMed  Google Scholar 

  94. Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182–186.

    Article  CAS  PubMed  Google Scholar 

  95. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2:721–728.

    CAS  PubMed  Google Scholar 

  96. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J Mol Med. 2006;17:323–329.

    CAS  PubMed  Google Scholar 

  97. Arts J, Angibaud P, Marien A, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97:1344–1353.

    Article  CAS  PubMed  Google Scholar 

  98. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–692.

    Article  CAS  PubMed  Google Scholar 

  99. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441:349–353.

    Article  CAS  PubMed  Google Scholar 

  100. Bibikova M, Chudin E, Wu B, et al. Human embryonic stem cells have a unique epigenetic signature. Genome Res. 2006;16:1075–1083.

    Article  CAS  PubMed  Google Scholar 

  101. Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr, Zimmer SG, Modesitt SC. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol. 2007;104:596–601.

    Article  CAS  PubMed  Google Scholar 

  102. Sonnemann J, Gange J, Pilz S, Stotzer C, Ohlinger R, Belau A, Lorenz G, Beck JF. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer. 2006;6:183.

    Article  PubMed  CAS  Google Scholar 

  103. Qian X, LaRochelle WJ, Ara G, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther . 2006;5:2086–2095.

    Article  CAS  PubMed  Google Scholar 

  104. Lin CT, Lai HC, Lee HY, et al. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008;99:1218–1226.

    Article  CAS  PubMed  Google Scholar 

  105. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–6044.

    CAS  PubMed  Google Scholar 

  106. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18:2335–2341.

    Article  CAS  PubMed  Google Scholar 

  107. Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18:1529–1538.

    Article  CAS  PubMed  Google Scholar 

  108. Lau OD, Kundu TK, Soccio RE, et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell. 2000;5:589–595.

    Article  CAS  PubMed  Google Scholar 

  109. Sansom OJ, Maddison K, Clarke AR. Mechanisms of disease: methyl-binding domain proteins as potential therapeutic targets in cancer. Nat Clin Pract Oncol. 2007;4:305–315.

    Article  CAS  PubMed  Google Scholar 

  110. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123–1136.

    Article  CAS  PubMed  Google Scholar 

  111. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol. 2001;21:4330–4336.

    Article  PubMed  Google Scholar 

  112. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21:1050–1063.

    Article  CAS  PubMed  Google Scholar 

  113. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res , 2008;68:4311–20.

    Google Scholar 

  114. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells – perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344.

    Article  CAS  PubMed  Google Scholar 

  115. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267–284.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge grant support from the U.S. National Institutes of Health, National Cancer Institute grants CA085289 (to K.P.N.), CA113001 (to T. T-H. H), Ovar'coming Together (Indianapolis, IN, to C.B.), the Walther Cancer Institute (Indianapolis, IN, to K.P.N.), and Phi Beta Psi Sorority (Brownsburg, IN, to K.P.N.)

Author information

Authors and Affiliations

  1. Medical Sciences, Indiana University, 47405, Bloomington, IN, USA

    Kenneth P. Nephew, Curt Balch, Shu Zhang & Tim H-M. Huang

  2. Indiana University Cancer Center, 46202, Indianapolis, IN, USA

    Kenneth P. Nephew

Authors
  1. Kenneth P. Nephew
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Curt Balch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tim H-M. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, University of Missouri, Hospital Dr. 1, Columbia, 65212, U.S.A.

    M. Sharon Stack

  2. School of Medicine, New York University, First Ave. 550, New York, 10016, U.S.A.

    David A. Fishman

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Nephew, K.P., Balch, C., Zhang, S., Huang, T.HM. (2009). Epigenetics and Ovarian Cancer. In: Stack, M., Fishman, D. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 149. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-98094-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-98094-2_6

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-98093-5

  • Online ISBN: 978-0-387-98094-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation